PT-112 for thymus gland tumors after prior chemotherapy
Part of Blood & lymphatic, Brain & nervous system, Cancer clinical trials.
This trial studies PT-112, a new treatment, in people with thymoma or thymic carcinoma that has grown despite at least one prior platinum chemotherapy treatment. It may help shrink tumors or slow disease progression, especially when surgery is not possible.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of thymoma or thymic carcinoma from a biopsy or surgery sample
- Your cancer has worsened after at least one prior platinum chemotherapy treatment, and it cannot be removed by surgery
- Your disease can be measured on scans (there must be at least one measurable spot)
- You are 18 or older, and your energy/activities are limited to ECOG 0–1 (you are not severely limited)
- Your blood counts and organs (kidneys, liver, and bone marrow) are strong enough for treatment
- You can sign informed consent and understand the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines surgery (burning away the tumor) with heated chemotherapy given directly into the chest to treat thymus gland tumors that have spread to the lining of the lung or chest wall. The goal is to remove the visible tumor and wash the area with heated chemo to help delay or prevent it from coming back.
This study tests giving chemotherapy directly into the chest (intrathoracic) during or after surgery to remove pleura tumors in people with thymoma or thymic cancer. It aims to see if this approach can reduce the chance of the cancer coming back.
This trial tests KC1036 in people with advanced thymoma or thymic carcinoma whose cancer came back or spread after their first standard chemotherapy. It may offer a new treatment option when earlier treatment no longer worked.
This trial tests a new drug, PTT-936, alone or with other treatments, for people with solid tumors that have spread or cannot be removed. It aims to see if the drug is safe and effective.
This study tests a combination of two drugs (tislelizumab and anlotinib) as a second treatment option for people with thymoma or thymic carcinoma whose cancer has worsened after first-line therapy. It aims to see if this combination can control the tumor and improve outcomes.
This study tests a new drug called sacituzumab tirumotecan for people with advanced thymus tumors that have already been treated once. The drug is given as an infusion and may help control the tumor.
Hear when a new Thymic Epithelial Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.